Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

The "Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region" report has been added to ...

The world of beauty is a vibrant one, with perfumes and makeup symbolizing glamour, confidence, and self-expression .

The short answer is yes, PCOS has a complex genetic predisposition. However, lifestyle and environmental factors also play a ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

STP-707 is under clinical development by Sirnaomics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate ...

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, ...

PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition ...

IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for ...

China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.